Chimeric Therapeutics : Change of Director's Interest Notice - JC, CE & GM

For personal use only

ASX Announcement

December 14, 2021

Change of Director's Interest Notices

Attached are Director's Interest Notices (Appendix 3Y) for Managing Director Jennifer Chow and Non-Executive Directors' Cindy Elkins and George Matcham, for the issue of unlisted options as approved by Shareholders at the Annual General Meeting held on 22 November 2021 to be issued within 30 days of shareholder approval.

Phillip Hains

Company Secretary

Appendix 3Y Change of Director's Interest Notice

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.	Amended 01/01/11
Name of Entity:		Chimeric Therapeutics Limited (ASX: CHM)
ABN:		68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Jennifer Chow
Date of Last Notice:	2 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Direct or Indirect Interest		Direct
	Nature of indirect interest		-
	Note: Provide details of the circumstances giving rise to
	(including r g stered holder)
	the relevant interest.
	Date of change		3 December 2021
	No. of securities held prior to change
			Shares			Options
			Direct	670,498	8,291,495
			Indirect	-		-
			Total	670,498	8,291,495
	Class		a) Fully Paid Ordinary Shares
			b) Unlisted Options.
	Number acquired
			Shares		Options
			Direct		a) 1,032,416		b) 2,000,000
			Indirect	-		-
			Total	1,032,416		2,000,000
	Number disposed
			Shares		Options
			Direct	-		-
			Indirect	-		-
			Total	-		-
+ See chapter 19 for defined terms.
01/01/2011						Appendix 3Y Page 1

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Note:	b) Non-cash, see 'nature of change' below.
Value/Consideration	a) $0.272 per share
If consideration is non-cash, provide details and
estimated valuation		Shares	Options
No. of securities held after change
	Direct	1,702,914	10,291,495
	Indirect	-	-
	Total	1,702,914	10,291,495
Example:	from previous employer as per section 9.8 of
N ture of change	a) Issue of shares as part of sign-on payment for
on-market trade, off-market trade, exercise of options,	forfeiture of long-term incentive payment
issue of securities under dividend reinvestment plan,	Prospectus lodged 18 January 2021.
participation in buy-back

b) Issue of options as approved by Chimeric Therapeutics Limited shareholders at the Annual General Meeting held on 22 November 2021.

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
Note: Details are only required for a contract in
in rest related prior to change
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Note: If consideration is non-cash, provide details	N/A
Value/Consideration
and an estimated valuation
Interest after change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Part 3 - Closed period

Were the interests in the securities or	No
contracts detailed above traded
during a +closed period where prior
written clearance was required?
If so, was prior written clearance	N/A
provided to allow the trade to proceed
during this period?
If prior written clearance was	N/A
provided, on what date was this
provided?

+ See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director's Interest Notice

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.	Amended 01/01/11
Name of Entity:		Chimeric Therapeutics Limited (ASX: CHM)
ABN:		68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Cindy Elkins
Date of Last Notice:	10 March 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest		Direct
Nature of indirect interest		-
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
Date of change		3 December 2021
No. of securities held prior to change
	Shares	Options
		Direct	-	-
		Indirect	24,800	-
		Total	24,800	-
Class		Unlisted Options.
Number acquired
	Shares	Options
		Direct	-	2,750,000
		Indirect	-	-
		Total	-	2,750,000
Number disposed
	Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

+ See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1